Radiation plus glofitamab for relapsed large B-cell lymphoma with large tumors
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of large B-cell lymphoma that is CD20-positive (a protein on the cancer cells) and has come back after or not responded to at least one prior treatment that included rituximab.
- You have a bulky tumor (larger than about 2.4 inches across) or a high total amount of active lymphoma on a PET scan.
- You are in fairly good health (able to do daily activities with little or no help).
- You have not had radiation to the chest or heart area before.
- You do not have active lymphoma in the brain or spinal fluid.
- You are not pregnant or breastfeeding and agree to use effective birth control during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
This trial combines a targeted antibody treatment called glofitamab with radiation therapy for people whose diffuse large B-cell lymphoma has come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
This study looks at how well a new drug called glofitamab works in real life for people with a type of lymphoma that has come back or not improved after treatment. It aims to see if the drug is safe and effective outside of a clinical trial setting.
This trial tests a combination of radiation therapy, lenalidomide, and glofitamab for people with a type of lymphoma called DLBCL that has not responded to or has returned after initial treatment. The goal is to see if this combination can help when other treatments have failed.
This trial combines two treatments for large b-cell lymphoma that has come back or not responded to previous therapy. Glofitamab is a drug that helps the immune system attack cancer cells, and CAR-T therapy uses your own white blood cells, which are modified in a lab to find and kill cancer cells. This study aims to see if the two treatments together are safe and effective.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.